Identification of pyrazolopyridazinones as PDEδ inhibitors

Citations Over TimeTop 10% of 2016 papers

Abstract

The prenyl-binding protein PDEδ is crucial for the plasma membrane localization of prenylated Ras. Recently, we have reported that the small-molecule Deltarasin binds to the prenyl-binding pocket of PDEδ, and impairs Ras enrichment at the plasma membrane, thereby affecting the proliferation of KRas-dependent human pancreatic ductal adenocarcinoma cell lines. Here, using structure-based compound design, we have now identified pyrazolopyridazinones as a novel, unrelated chemotype that binds to the prenyl-binding pocket of PDEδ with high affinity, thereby displacing prenylated Ras proteins in cells. Our results show that the new PDEδ inhibitor, named Deltazinone 1, is highly selective, exhibits less unspecific cytotoxicity than the previously reported Deltarasin and demonstrates a high correlation with the phenotypic effect of PDEδ knockdown in a set of human pancreatic cancer cell lines.

Related Papers

• → Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer(2021)37 cited
• → Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.(2020)3 cited
• → Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer(2020)2 cited
• → Lung Cancer and <i>KRAS</i> -Its Molecular Biology/Genetics and Therapeutic Strategy-(2022)
• → 127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma(2022)